Arrowhead Pharmaceuticals
Clinical trials sponsored by Arrowhead Pharmaceuticals, explained in plain language.
-
New kidney drug enters early human testing
Disease control OngoingThis early-stage study tests a new drug, ARO-CFB, in healthy people and patients with IgA nephropathy, a kidney disease. The main goal is to check safety and how the drug moves through the body. Participants receive either the drug or a placebo.
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 07:50 UTC
-
New drug aims to slash stubborn cholesterol in rare genetic disease
Disease control OngoingThis study tests an experimental drug called ARO-ANG3 in 18 adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing dangerously high cholesterol. Participants receive two doses of the drug and are monitored for 36 weeks to see if it safely lo…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 07:38 UTC
-
New shot every 3 months could tame dangerous fat levels in blood
Disease control OngoingThis study tests an injectable drug called plozasiran in 446 adults with severely high triglycerides (a type of fat in the blood). Participants receive either the drug or a placebo every three months for a year. The goal is to see if the drug safely lowers triglyceride levels and…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Hepatitis b drug study halted before it began
Disease control TerminatedThis study planned to test a new drug called ARC-520 in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could lower a key virus marker (HBsAg) more effectively. However, the study was withdrawn before a…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Promising liver treatment trial for rare disease pulled before start
Disease control TerminatedThis study aimed to test a new drug called ARC-AAT in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can cause liver and lung damage. The drug was designed to lower harmful protein levels in the blood and liver. However, the trial was withdrawn before any pa…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New shot every 3 months could tame dangerous blood fats
Disease control OngoingThis study tests a new medicine called plozasiran, given as an injection every 3 months, to lower high triglycerides (a type of blood fat) in adults. About 1,456 people will receive either the drug or a placebo for a year. The goal is to see if the drug safely reduces triglycerid…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New shot could tame rare fat disorder and stop pancreas attacks
Disease control OngoingThis study tests a new medicine called plozasiran in 75 adults with familial chylomicronemia syndrome (FCS), a rare genetic condition causing extremely high blood fats. The goal is to see if the drug safely lowers triglycerides and reduces the risk of pancreatitis. Participants r…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:30 UTC
-
New drug plozsiran aims to tame dangerous blood fat levels
Disease control OngoingThis study tests a new drug called plozsiran in adults with severe hypertriglyceridemia, a condition where blood fat levels are dangerously high. Participants receive either the drug or a placebo every 3 months for a year. The goal is to see if plozsiran safely lowers triglycerid…
Phase: PHASE3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated May 04, 2026 16:20 UTC